JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2006, 55(4):160-167

Angiotensin Converting Enzyme Inhibitors

M. Šramko, M. Remko
Univerzita Komenského v Bratislave, Farmaceutická fakulta, Katedra farmaceutickej chémie, Slovenská republika

Angiotensin converting enzyme (ACE) is a zinc metallopeptidase which plays a key role in the regulation of important vasoactive peptides through its proteolytic activity. Effective inhibitors of ACE were until recently designed in the absence of the solved 3D structure of this enzyme. About 15 ACE inhibitors are currently commercially available, all of which nonspecifically inhibit both active domains of ACE. Vasopeptidase inhibitors are mixed inhibitors of ACE and neutral endopeptidase (NEP). They contemporarily inhibit the catalytic function of two enzymes and currently are undergoing clinical trials exhibiting better efficacy in the treatment of hypertension and cardiovascular diseases, but in the same time higher risk of adverse side effects compared to ACE inhibitors.

Keywords: angiotensin converting enzyme inhibitors; RAAS; neutral endopeptidase; vasopeptidase inhibitors

Received: February 10, 2006; Accepted: March 15, 2006; Published: April 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Šramko M, Remko M. Angiotensin Converting Enzyme Inhibitors. Čes. slov. farm. 2006;55(4):160-167.
Download citation

References

  1. Valle, B. L., Auld, D. S.: Biochemistry, 1990; 29, 5647 až 5659.
  2. Spyroulias, G. A., Galanis, A. S., Pairas, G. et al.: Curr. Top. Med. Chem., 2004; 4, 403-429. Go to original source... Go to PubMed...
  3. Eriksson, U., Danilczyk, U., Penniger, J. M.: Current Biology, 2002; 12, R745-R752. Go to original source... Go to PubMed...
  4. Abassi, Z. A., Tate, J. E., Golombe, E., Keiser, H. R.: Hypertension, 1992; 20, 89-95. Go to original source... Go to PubMed...
  5. Kenny, A. J., Stephanson, S. L.: FEBS Lett., 1998; 232, 1-8. Go to original source... Go to PubMed...
  6. Holland, D. R., Hausrath, A. C., Juers, D., Mathews, B. W.: Protein Sci., 1995; 4, 1955-1965. Go to original source... Go to PubMed...
  7. Colman, P. M., Jansonius, J. N., Matthews, B. W.: J. Mol. Biol., 1972; 70, 701-724. Go to original source... Go to PubMed...
  8. Steitz, T. A., Ludwig, M. L., Quiocho, F. A., Lipscomb, W. N.: J. Biol. Chem., 1967; 242, 4662-4668. Go to original source...
  9. Natesh, R., Schwager, S. L. U., Sturrock, E. D., Acharaya, K. R.: Nature, 2003; 421, 551-554. Go to original source... Go to PubMed...
  10. Oefner, C., DęArcy, A., Hennig, M. et al.: J. Mol. Biol., 2000; 296, 341-349. Go to original source... Go to PubMed...
  11. Spyroulias, G. A., Cordopatis, P.: Current Enzyme Inhibition, 2005; 1, 29-42. Go to original source...
  12. Hooper, N. M.: FEBS Lett., 1994; 354, 1-6. Go to original source... Go to PubMed...
  13. Hubert, C., Houot, A.-M., Corvol, P., Soubrier, F.: J. Biol. Chem., 1991; 266, 15377-15383. Go to original source...
  14. Corvol, P., Williams, T. A.: In: Cell-surface Peptidases in Health and Disease, Kenney, A. J., Boustead, C. M. (eds.): Oxford, BIOS Scientific Publishers Limited, 1997, s. 99.
  15. Erdos, E. G.: Hypertension, 1990; 16, 363-370. Go to original source... Go to PubMed...
  16. Ferrario, C. M., Chappel, M. C., Tallant, E. A., Brosnihan, K. B.: Hypertension, 1997; 30, 535-541. Go to original source... Go to PubMed...
  17. Rousseau, A., Michaud, A., Chauvet, M. T. et al.: J. Biol. Chem., 1995; 270, 3656-3661. Go to original source... Go to PubMed...
  18. Blais, C. Jr., Marceau, F., Rouleau, J. L., Adam, A.: Peptides, 2000; 21, 1903-1940. Go to original source... Go to PubMed...
  19. Remko, M.: Medicínska chémia. Bratislava, SAP, 2002, s. 99.
  20. Smieško, M.: Molecular Modeling Study of ACE inhibitors. Dizertačná práca (PhD.), 2002.
  21. Smieško, M., Remko, M.: Pharma Journal, 2003; 13, 72-76.
  22. Natesh, R., Schwager, S. L., Evans, H. R. et al.: Biochemistry, 2004; 43, 8718-8724. Go to original source... Go to PubMed...
  23. Georgiadis, D., Cuniasse, P., Cotton, J. et al.: Biochemistry, 2004; 43, 8048-8054. Go to original source... Go to PubMed...
  24. Vickers, C., Hales, P., Kaushik, V. et al.: J. Biol. Chem., 2002; 277, 14838-14843. Go to original source... Go to PubMed...
  25. Molinaro, G., Rouleau, J. L., Adam, A.: Curr. Opin. Pharmacol., 2002; 2, 131-141. Go to original source... Go to PubMed...
  26. Tipnis, S. R., Hooper, N. M., Hyde, R. et al.: J. Biol. Chem., 2000; 275, 33238-33243. Go to original source... Go to PubMed...
  27. Towler, P., Staker, B., Prasad, S. G. et al.: J. Biol. Chem., 2004; 279, 17996-18007. Go to original source... Go to PubMed...
  28. Turner, A. J., Hooper, N. M.: Trendss Pharmacol. Sci., 2002; 23, 177-183. Go to original source... Go to PubMed...
  29. The HYP Consortium 1995 Nature Genet., 1995; 11, 130 až 136. Go to original source...
  30. Emoto, N., Yanagisawa, M.: J. Biol. Chem., 1995; 270, 15262-15268. Go to original source... Go to PubMed...
  31. Roques, B. P., Noble, F., Daugé, V. et al.: Pharmacol. Rev., 1993; 45, 87-146. Go to original source...
  32. Pham, I., El Amrani, A. I. K., Fournié-Zaluski, M. C. et al.: J. Pharmacol. Exp. Ther., 1993; 265, 1339-1347. Go to original source...
  33. Jansen, W. M., de Zeeuw, D., van der Hem, G. K., de Jong, P. E.: Hypertension, 1989; 13, 640-646. Go to original source... Go to PubMed...
  34. Burnett, J. C. Jr, Kao, P. C., Hu, D. C. et al.: Science, 1986; 231, 1145-1147. Go to original source... Go to PubMed...
  35. Burnett, J. C.: J. Hypertens., 1999; 17, s37-s43. Go to original source... Go to PubMed...
  36. Roques, B. P., Beaumont, A.: Trends Pharmacol. Sci., 1990; 11, 245-249. Go to original source... Go to PubMed...
  37. Oefner, C., Roques, B. P., Fournié-Zaluski, M. C., Dale, G. E.: Acta Crystallogr. Biol. Crystallogr., 2004; 60, 392-396. Go to original source... Go to PubMed...
  38. Cushman, D. W., Ondetti, M. A.: Nat. Med., 1990; 5, 1110-1113. Go to original source... Go to PubMed...
  39. Ondetti, M. A., Rubin, B., Cushman, D. W.: Science, 1977; 196, 441-444. Go to original source... Go to PubMed...
  40. Napoli, C., Sica, V., de Nigris, F. et al.: Am. Heart J., 2004; 148, e5. Go to original source... Go to PubMed...
  41. Remko, M.: Metódy výskumu a vývoja liečiv. Bratislava, SAP, 1999, s. 52.
  42. Leonetti, G., Cuspidi, C.: Drugs, 1995; 49, 516-535. Go to original source... Go to PubMed...
  43. Richards, A. M., Wittert, G. A., Crozier, I. G. et al.: J. Hypertens., 1993; 11, 407-416. Go to original source... Go to PubMed...
  44. Northridge, D. B., Newby, D. E., Rooney, E. et al.: Am. Heart J., 1999; 138, 1149-1157. Go to original source... Go to PubMed...
  45. Trippodo, N. C., Robl, J. A., Asaad, M. M. et al.: J. Pharmacol. Exp. Ther., 1995; 275, 745-752. Go to original source...
  46. Wallis, E. J., Ramsay, L. E., Hettiarachchi, J.: Clin. Pharmacol. Ther., 1998, 64, 439-449. Go to original source... Go to PubMed...
  47. Weber, M.: Am. J. Hypertens., 1999, 12, 139S-147S. Go to original source... Go to PubMed...
  48. Sagnella, G. A.: J. Renin Angiotensin Aldosterone Syst., 2002, 3, 90-95. Go to original source... Go to PubMed...
  49. Kostis, J. B., Packer, M., Black, H. R. et al.: Am. J. Hypertens., 2004, 17, 103-111. Go to original source... Go to PubMed...
  50. Packer, M., Califf, R. M, Konstam, M. A. et al.: Circulation, 2002; 106, 920-926. Go to original source... Go to PubMed...
  51. Smieško, M., Remko, M.: Čes. slov. Farm., 1999; 48, 247-251. Go to original source...
  52. Smieško, M., Remko, M.: Chem. Papers, 2002; 56, 138-143.
  53. Smieško, M., Remko, M.: Chem. Papers, 2004; 58, 71-78. Go to original source...
  54. Šramko, M., Remko, M., Garaj, V.: Struct. Chem., 2005; 16, 391-399. Go to original source...
  55. Rella, M., Rushworth, C. A., Guy, J. L., Turner, A. J., Langer, T., Jackson, R. M.: J. Chem. Inf. Model 10 (2006) v tlači.
  56. Kuster, D. J., Marshall, G. R.: J. Comput. Aided Mol. Des. 19, 609-615 (2005). Go to original source... Go to PubMed...




Czech and Slovak Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.